Berberine protects C57BL/6J mice against ethanol withdrawal-induced hyperexcitability

Phytotherapy Research

Volumn 25, Issue 2, 2011, Pages 302-307

  Bhutada, Pravinkumar ^a   Mundhada, Yogita ^a   Bansod, Kuldeep ^a   Hiware, Rahul ^a   Rathod, Sumit ^a   Dixit, Pankaj ^b   Mundhada, Dharmendra ^a  

^a Agnihotri College of Pharmacy Wardha   (India)

^b IPS Academy   (India)

Author keywords

berberine; diazepam; drug addiction; ethanol dependence; ethanol withdrawal; hyperexcitability

Indexed keywords

BERBERINE; DIAZEPAM;

ACUTE DRUG ADMINISTRATION; ALCOHOL CONSUMPTION; ALCOHOL WITHDRAWAL; ALCOHOLISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG DOSE COMPARISON; DRUG MECHANISM; MALE; MOUSE; NEUROMODULATION; NONHUMAN; NUTRIENT;

ANIMALS; BERBERINE; DIAZEPAM; ETHANOL; MALE; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; PSYCHOMOTOR AGITATION; SUBSTANCE WITHDRAWAL SYNDROME;

MUS;

EID: 79551675123     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.3272     Document Type: Article

References (37)

1. Ait-Daoud N Jr, Malcolm RJ, Johnson BA,. 2006. An overview of medications for the treatment of alcohol withdrawal and alcohol dependence with an emphasis on the use of older and newer anticonvulsants. Addict Behav 31: 1628-1649.
2. Besheer J, Lepoutre V, Hodge CW,. 2009. Preclinical evaluation of riluzole: assessments of ethanol self-administration and ethanol withdrawal symptoms. Alcohol Clin Exp Res 33: 1460-1468.
3. Bhutada P, Mundhada Y, Bansod K, Dixit P, Umathe S, Mundhada D,. 2010a. Anticonvulsant activity of berberine, an isoquinoline alkaloid in mice. Epilepsy Behav [DOI: 10.1016/j.yebeh.2010.03.007].
4. Bhutada PS, Mundhada YR, Bansod KU, et al. 2010b. Inhibitory influence of mecamylamine on ethanol withdrawal-induced symptoms in C57BL/6J mice. Behav Pharmacol 21: 90-95.
5. Castillo J, Hung J, Rodriquez M, Bastidas E, Laboren I, Jaimes A,. 2005. LED fluorescence spectroscopy for direct determination of monoamine oxidase B inactivation. Anal Biochem 343: 293-298.
6. Chastain G,. 2006. Alcohol, neurotransmitter systems, and behavior. J Gen Psychol 133: 329-335.
7. Costall B, Kelly ME, Naylor RJ,. 1988. The anxiolytic and anxiogenic actions of ethanol in a mouse model. J Pharm Pharmacol 40: 197-202.
8. De Biasi M, Salas R,. 2008. Influence of neuronal nicotinic receptors over nicotine addiction and withdrawal. Exp Biol Med 233: 917-929.
9. File SE, Zharkovsky A, Hitchcott PK,. 1992. Effects of nitrendipine, chlordiazepoxide, flumazenil and baclofen on the increased anxiety resulting from alcohol withdrawal. Prog Neuropsychopharmacol Biol Psychiatry 16: 87-93.
10. Gatch MB, Lal H,. 1998. Pharmacological treatment of alcoholism. Prog Neuropsychopharmacol Biol Psychiatry 22: 917-944.
11. Gulliver SB, Kamholz BW, Helstrom AW,. 2006. Smoking cessation and alcohol abstinence: what do the data tell us? Alcohol Res Health 29: 208-212.
12. Harsing LG, Lonart G, Vizi SE,. 1988. Berbanes: search for novel alpha-2 adrenoceptor antagonists. Pol J Pharmacol Pharm 40: 697-708.
13. Jung ME, Wallis CJ, Gatch MB, Lal H,. 2000. Abecarnil and alprazolam reverse anxiety-like behaviors induced by ethanol withdrawal. Alcohol 21: 161-168.
14. Kiefer F, Mann K,. 2005. New achievements and pharmacotherapeutic approaches in the treatment of alcohol dependence. Eur J Pharmacol 526: 163-171.
15. Koob GF, Nestler EJ,. 1997. The neurobiology of drug addiction. J Neuropsychiatry Clin Neurosci 9: 482-497.
16. Kulkarni SK, Dhir A,. 2007. Possible involvement of l-arginine-nitric oxide (NO)-cyclic guanosine monophosphate (cGMP) signaling pathway in the antidepressant activity of berberine chloride. Eur J Pharmacol 569: 77-83.
17. Kulkarni SK, Dhir A,. 2010. Berberine: a plant alkaloid with therapeutic potential for central nervous system disorders. Phytother Res 24: 317-324.
18. Lee B, Hahm DH, Lee HJ, Shim I,. 2002. Effect of Coptidis Rhizoma on repeated cocaine-induced behavioral sensitization and fos like immunoreactivity in the brain of the rats. Korean J Biol Physiol Psychol 13: 57-69.
19. Lee B, Yang CH, Hahm DH, et al. 2007. Coptidis Rhizoma attenuates repeated nicotine-induced behavioral sensitization in the rat. J Pharm Pharmacol 59: 1663-1669.
20. Lee SY, Song DK, Jang CG,. 2003. Effects of Coptis Japonica on morphine-induced conditioned place preference in mice. Arch Pharmacal Res 26: 540-544.
21. Li Z, Wei Y, Chu T, et al. 2005. Radioiodination, biodistribution and pharmacokinetics of berberine in mice. J Radioanal Nucl Chem 265: 355-359.
22. Littleton J,. 1998. Neurochemical mechanisms underlying alcohol withdrawal. Alcohol Health Res World 22: 13-24.
23. Mayo-Smith MF,. 1997. Pharmacological management of alcohol withdrawal. A meta-analysis and evidence-based practice guideline. American Society of Addiction Medicine Working Group on pharmacological management of alcohol withdrawal. JAMA 278: 144-151.
24. Nagy J,. 2008. Alcohol related changes in regulation of NMDA receptor functions. Curr Neuropharmacol 6: 39-54.
25. Olive MF, Becker HC,. 2008. Effects of the mGluR2/3 agonist LY379268 and the mGluR5 antagonist MPEP on handling-induced convulsions during ethanol withdrawal in mice. Alcohol 42: 191-197.
26. Ortiz J, Fitzgerald LW, Charlton M, et al. 1995. Biochemical actions of chronic ethanol exposure in the mesolimbic dopamine system. Synapse 21: 289-298.
27. Peng WH, Lo KL, Lee YH, Hung TH, Lin YC,. 2007. Berberine produces antidepressant-like effects in the forced swim test and in the tail suspension test in mice. Life Sci 81: 933-938.
28. Piasecki TM, Jorenby DE, Smith SS, Fiore MC, Baker TB,. 2003. Smoking withdrawal dynamics. I. Abstinence distress in lapsers and abstainers. J Abnorm Psychol 112: 3-13.
29. Schuckit MA, Anthenelli RM, Bucholz KK, Hesselbrock VM, Tipp J,. 1995. The time course of development of alcohol-related problems in men and women. J Stud Alcohol 56: 218-225.
30. Umathe SN, Bhutada PS, Dixit PV, Jain NS,. 2008. Leuprolide-a luteinizing hormone-releasing hormone agonist attenuates ethanol-withdrawal syndrome and ethanol-induced locomotor sensitization in mice. Neuropeptides 42: 345-353.
31. Uzbay IT,. 2008. Serotonergic anti-depressants and ethanol withdrawal syndrome: a review. Alcohol Alcohol 43: 15-24.
32. Verleye M, Heulard I, Gillardin JM,. 2009. The anxiolytic etifoxine protects against convulsant and anxiogenic aspects of the alcohol withdrawal syndrome in mice. Alcohol 43: 197-206.
33. Wang X, Wang R, Xing D, et al. 2005. Kinetic difference of berberine between hippocampus and plasma in rat after intravenous administration of Coptidis rhizoma extract. Life Sci 77: 3058-3067. (Pubitemid 41423743)
34. West RJ, Hajek P, Belcher M,. 1989. Severity of withdrawal symptoms as a predictor of outcome of an attempt to quit smoking. Psychol Med 19: 981-985.
35. WHO. 2004. Global status report on alcohol. World Health Organization, Department of Mental Health and Substance Abuse;. accessed on: June 2009.
36. Xu X, Malave A,. 2001. Protective effect of berberine on cyclophosphamide-induced haemorrhagic cystitis in rats. Pharmacol Toxicol 88: 232-237.
37. Yoo JH, Yang EM, Cho JH, et al. 2006. Inhibitory effects of berberine against morphine-induced locomotor sensitization and analgesic tolerance in mice. Neuroscience 142: 953-961.